Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for RET fusion-positive non-small-cell lung cancer, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Solvent-front resistance mutations have no approved inhibitor.
Nothing recorded yet.
Nothing recorded yet.
Background: Oligoprogression, On-target resistance mutations (gatekeeper, solvent-front, compound). Also on OnCo: Resistance atlas · Lines of therapy.
Whether adjuvant selpercatinib prevents recurrence is not yet known.
RNA-based testing is needed to find all fusions but is not universally available.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
PFS HR 0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.